Delaying rule to fast-track breakthrough devices only ‘kicks the can down the road,’ imaging advocate says
Delaying rule to fast-track breakthrough devices only ‘kicks the can down the road,’ imaging advocate says Matt O’Connor | May 20, 2021 | Economics & Policy A top medical imaging advocate on Thursday expressed its displeasure with the federal government’s recent decision to delay implementation of a rule that would expedite patient access to “breakthrough” devices in imaging and other specialties. The Medical Imaging and Technology Alliance said it’s concerned with the Centers for Medicare & Medicaid Services’ move to postpone the final rule until Dec. 15. On Friday, May 14, Health and Human Services said it agreed with stakeholders’ apprehensions received during a since-closed public comment period. Finalized in January, the Medicare Coverage Innovative Technology rule would eliminate lag time between FDA approval of innovative technologies and Medicare coverage. At that point in time, MITA celebrated its finalization as a “major regulatory win.” “We are greatly disappointed by the CMS decision to postpone implementation of MCIT,” Executive Director Patrick Hope said Thursday. “Further delaying this coverage pathway effectively denies patient access to breakthrough technologies and ‘kicks the can down the road,’ leaving patients, healthcare providers, and medical device innovators in limbo.” HHS officials said the extra time will go toward addressing commenter’s anxieties, including protecting Medicare patients and solidifying coordination between coverage, coding and payment. Earlier this year the Biden administration punted the rule’s start date to May 15, making this the second such delay. The American College of Radiology had previously expressed its own worries about the rule while manufacturing groups, such as the Advanced Medical Technology Association or AdvaMed, have urged policymakers to implement MCIT as soon as possible. “Despite our concerns, we will continue our engagement with the agency to support the implementation of MCIT before the end of 2021,” Hope said in a May 20 update. Email this author Around the web AI IN HEALTHCARE Because they learn as they go, machine learning models for drug discovery have to be continuously re-trained for changing conditions in drug production processes. By Dave Pearson June 01 CARDIOVASCULAR BUSINESS PCI may be seen as a “reasonable alternative to CABG” for many elderly patients, the research team observed. By Michael Walter June 01 RADIOLOGY BUSINESS The ABR has not yet determined whether remote testing will continue in 2023, a spokesman said. By Marty Stempniak May 28 RADIOLOGY BUSINESS Hyperpolarized xenon MRI enables sensitive, regional investigation of breathing and gas transfer into the blood stream, according to a new study in Radiology. By Marty Stempniak May 28 RELATED ARTICLES ON ECONOMICS & POLICY
Read the full article at: www.healthimaging.com
Who We Are
Omnica Corporation is a privately-held design, engineering, and medical product development firm located in Irvine, California. The 28-person company is staffed with full-time employees and has been in operation since 1984. Our speciality is custom product development for the medical industry and industrial fields.
Our expertise is developing complex medical devices.Technical personnel at Omnica includes designers, mechanical engineers, electronic and software engineers, advanced R&D specialists, regulatory staff (for FDA documentation), machinists and model makers.